Treatment of psoriatric arthritis and therapeutic perspectives;Traitement du rhumatisme psoriasique et perspectives thérapeutiques

Revue du Rhumatisme (Edition Francaise)

Volumn 69, Issue 6, 2002, Pages 676-681

  Goupille, Philippe ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

Anti TNF ; Controlled studies; Psoriatic arthritis; Treatment

Indexed keywords

EID: 0012277381     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1169-8330(02)00357-5     Document Type: Short Survey

References (40)

1. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis : the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994 ; 21 : 2286-91.
2. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining lunctional ability in ankylosing spondylitis : the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994 ; 21 : 2281-5.
3. Claudepierre P, Sibilia J, Goupille P, Flipo RM, Wendling D, Eulry F, et al. Evaluation of a French version of the Bath Ankylosing Spondylitis Disease Activity Index in patients with spondyloarthropathy. J Rheumatol 1997 ; 24 : 1954-8.
4. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo for the treatment of psoriatic arthritis and cutaneous psoriasis. Arthritis Rheum 1996 ; 39 : 2013-20.
5. Combe B, Goupille P, Kuntz JL, Tebib J, Lioté F, Brégeon C. Sulfasalazine in psoriatic arthritis : a randomized, multicentre, placebo-controlled study. Br J Rheumatol 1996 ; 35 : 664-8.
6. Farr M, Kiras GD, Waterhouse, Jubb R, Felix-Davies D, Bacon PA. Sulphasalazine in psoriatic arthritis : a double-blind placebo-controlled study. Br J Rheumatol 1990 ; 29 : 46-9.
7. Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA. Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol 1990 ; 32 : 923-5.
8. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, et al. Sulfasalazine therapy for psoriatic arthritis : a double-blind, placebo controlled trial. J Rheumatol 1995 ; 22 : 894-8.
9. Dorwart BB, Gall EP, Schumacher HR, Krauser RE. Chrysotherapy in psoriatic arthritis. Arthritis Rheum 1978 ; 21 : 513-5.
10. Richter MB, Kinsella P, Corbett M. Gold in psoriatic arthropathy. Ann Rheum Dis 1980 ; 39 : 279-80.
11. Carette S, Calin A, Mc Cafferty JP, Wallin BA. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthritis Rheum 1989 ; 32 : 158-65.
12. Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990 ; 29 : 280-3.
13. Seideman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol 1987 ; 14 : 777-9.
14. McKendry RJR, Kraag G, Seigel S, Al-Awadhi A. Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis. Ann Rheum Dis 1993 ; 52 : 826-8.
15. Kammer GM, Soter NA, Gibson DJ, Schur PH. Psoriatic arthritis : a clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum 1979 ; 9 : 75-97.
16. Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992 ; 19 : 1724-6.
17. McKenzie AH, Scherbel AL. Chloroquine and hydroxychloroquine in rheumatological therapy. Clin Rheum Dis 1980 ; 6 : 545-66.
18. Sayer ME, Mazanec DJ. Use of antimalarial drugs for the treatment of psoriatic arthritis. Am J Med 1992 ; 93 : 474-5.
19. Black RL, O'Brien WM, Van Scott EJ. Mediotrexate therapy in psoriatic arthritis. JAMA 1964 ; 189 : 743-7.
20. Chaouat Y, Kanovitch B, Faures, Grupper C, Bourgeois-Spinasse J. Le rhumatisme psoriasique. Traitement par le méthotrexate. Rev Rhum Mal Ostéoartic 1971 ; 38 : 453-60.
21. Kragballe K, Zachariae E, Zachariae H. Mediotrexate in psoriatic arthritis : a retrospective study. Acta Dermatol Venereol 1983 ; 63 : 165-7.
22. Zachariae H, Zachariae E. Mediotrexate treatment of psoriatic arthritis. Acta Dermatol Venereol 1987 ; 67 : 270-3.
23. Wilkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984 ; 27 : 376-81.
24. Espinoza CG, Zakraoui L, Espinoza CG, Gutierrez F, Jara LJ, Silveira LH, et al. Psoriatic arthritis : clinical response and side effects to methotrexate therapy. J Rheumatol 1992 ; 19 : 872-7.
25. Gupta AK, Matteson EL, Ellis C, Ho VC, Tellner DC, Voorhees JJ, et al. Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol 1989 ; 125 : 507-10.
26. Mahrle G, Schulze HJ, Brautigam M, Mischer P, Schopf R, Jung EG, et al. Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study. Br J Dermatol 1996 ; 135 : 752-7.
27. Steinsson K, Jonsdottir I, Valdimarsson H. Cyclosporin A in psoriatic arthritis : an open study. Ann Rheum Dis 1990 ; 49 : 603-6.
28. Menkès CJ, Simon F, Delbarre F. Traitement de la polyarthrite psoriasique par l'azathioprine. Nouv Presse Med 1975 ; 4 : 585.
29. Feldges D, Barnes CG. Treatment of psoriasis arthropathy with either azathioprine or methotrexate. Rheum Rehab 1974 ; 13 : 120-4.
30. Le Quintrec JL, Menkès CJ, Amor B. Rhumatisme psoriasique grave. Traitement par l'azathioprine. À propos de 11 cas. Rev Rhum Mal Ostéoartic 1990 ; 57 : 815-9.
31. Scarpa R, Manguso F, Oriente A, Peluso R, Oriente P. Leflunomide in psoriatic polyarthritis. An Italian pilot stud [abstract]. Arthritis Rheum 2001 ; 44 (Suppl) : 239.
32. Liang GC, Barr WG. Long term follow-up of the use of leflunomide (LF) in recalcitrant psoriatic arthritis and psoriasis [abstract]. Arthritis Rheum 2001 ; 44 (Suppl) : 413.
33. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000 ; 18 : 732-4.
34. Mease PJ, Goffe BS, Metz J, Van der Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis : a randomised trial. Lancet 2000 ; 356 : 385-90.
35. Mease PJ, Goffe BS, Metz J, Van der Stoep A, Finck B, Burge DJ. Enbrel® (Etanercept) in patients with psoriatic arthritis and psoriasis [abstract]. Arthritis Rheum 2000 ; 43 (Suppl) : 403.
36. Mease PJ, Kivitz A, Burch F, Siegel E, Cohen S, Burge D. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel®) : results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum 2001 ; 44 (Suppl) : 226.
37. Van den Bosch F, Kruithof E, Baeten, De Keyser F, Mielants H, Veys EM. Effects of loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy : an open pilot study. Ann Rheum Dis 2000 ; 59 : 428-33.
38. Ogilvie ALJ, Antoni C, Dechant C, Wendler J, Lueftl M, Lorenz HM, et al. Treatment of psoriatic arthritis with antitumour necrosis factor α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001 ; 144 : 587-9.
39. Brockbank JE, Lapp V, Gladman DD. Infliximab therapy in 15 patients with psoriatic arthritis (PsA). Abstract no. 092, International League of Associations for Rheumatology 2001, 26-30 Août, Edmonton, 2001.
40. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis : a randomised trial. Lancet 2001 ; 357 : 1842-7.